CATALYST BIOSCIENCES INC (CBIO)       0.295  -0.01 (-2.99%)

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. The firm's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT. The firm's product MarzAA is a subcutaneously (SQ) administered next generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. The firm's DalcA is a next generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. Its CB 2679d-GT is an Adeno-associated virus (AAV)-based gene therapy construct harboring the DalcA sequence. The firm's SQ product candidates demonstrate a prolonged duration of activity enabling them to provide continuous therapeutic levels.

Company Info

CATALYST BIOSCIENCES INC

611 Gateway Blvd Ste 710

South San Francisco CALIFORNIA 94080

P: 16508710761.0

CEO: Nassim Usman

Employees: 45

Website: http://www.catalystbiosciences.com/